-
Cantor Lowers Price Target On Trulieve Post Harvest Merger Projecting Disrupted Near-Term Performance
Monday, October 4, 2021 - 9:19am | 695Trulieve Cannabis Corp (OTCQX: TCNNF) confirmed Friday that it had completed its previously announced billion-dollar merger with Harvest Health & Recreation Inc. (OTCQX: HRVSF), creating “the largest and most profitable cannabis operation in the U.S....
-
Cantor Fitzgerald Says Columbia Care Could Be Attractive To Canadian Companies, Lowers Price Target Ahead Of Company Earnings
Wednesday, August 4, 2021 - 12:54pm | 534Year-to-date, Columbia Care Inc.'s (NEO: CCHW) (OTCQX: CCHWF) shares lost 26.12%. The multi-state operator recently had several acquisition moves including the closing of $240 million worth purchase of privately-held cannabis company Green Leaf Medical,...
-
Bluebird Bio Shares Down 10%; Cantor Downgrades Stock To Sell
Friday, October 14, 2016 - 11:56am | 296Cantor Fitzgerald wasn’t impressed by bluebird bio inc (NASDAQ: BLUE)’s investor day event on Thursday. Analyst Elemer Piros downgraded the stock to Sell following the event and doesn’t expect any new data from the company at the upcoming ASH conference in December. According...
-
263% Upside Seen In Abeona Therapeutics
Wednesday, September 21, 2016 - 1:00pm | 241Cantor Fitzgerald reiterated its Buy rating and $21 price target on the shares of Abeona Therapeutics Inc (NASDAQ: ABEO). The catalyst being the company's announcement of licensing of a next generation gene vector delivery system along with a clinical trial-ready therapy for Batten disease...
-
Cantor Fitzgerald Likes Alibaba Ahead Of Q1 Earnings Release
Monday, August 8, 2016 - 11:49am | 285Cantor Fitzgerald expects in-line result from Alibaba Group Holding Ltd (NYSE: BABA) when it reports its first-quarter numbers on August 11. The Street expects adj. EPS of $0.62 on revenue of $4.526 billion (41 percent year-over-year). The brokerage projects EPS/revenue of $0.73/$4.147 billion (+27...
-
Cantor Sees Facebook's Ad Revenue 3x Higher Than Overall Market
Tuesday, July 26, 2016 - 1:39pm | 317In the midst of a very busy earnings season, Facebook Inc (NASDAQ: FB) will be one of the most important releases this week. While the Pokemon Go craze has highlighted the vulnerability social media apps can experience due to new trends, Facebook still remains one of the most solid investments...
-
Intercept Shares Turn Negative Following Mid-Day Sell Rating From Cantor
Wednesday, July 6, 2016 - 3:57pm | 177Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares took an intra-day turn lower Wednesday after Cantor Fitzgerald issued a concerning mid-day note on the name. Shares had been trading in positive territory for a couple hours ahead of the new sell-side recommendation; the stock last traded down...
-
Cantor Still Recommending A Buy For T2 BioSystems
Monday, June 20, 2016 - 4:00pm | 249Cantor Fitzgerald maintained its Buy rating on T2 Biosystems Inc (NASDAQ: TTOO) following the American Society for Microbiology (ASM) Microbe 2016 Conference. Moreover, the company reports that the T2Bacteria trial remains on track, which the brokerage believes may support T2Dx adoption in the...
-
Cantor Fitzgerald Sees 81% Upside In Spark Therapeutics; Initiating with A Buy
Friday, June 3, 2016 - 9:18am | 340Cantor Fitzgerald said Spark Therapeutics Inc (NASDAQ: ONCE) could become the first company with an approved gene therapy product in the United States. The brokerage initiated the company with a Buy rating and $100 price target. Cantor Fitzgerald's target price implies a potential upside of...
-
Is Yahoo Getting Close To The Finish Line?
Friday, April 8, 2016 - 10:45am | 577Is Yahoo! Inc. (NASDAQ: YHOO) getting closer to the finish line? Yes, according to analysts at Cantor Fitzgerald. Preliminary bids for Yahoo are due on Monday, April 11. There are reports of more than 40 interested parties, including Verizon Communications Inc. (NYSE: VZ), AT&T Inc. (NYSE:...
-
Cantor: Relypsa Sale Makes Sense
Thursday, April 7, 2016 - 3:10pm | 190Analysts at Cantor said the potential sale of Relypsa Inc (NASDAQ: RLYP) makes sense. Earlier, Reuters reported the biopharma company is exploring a sale following a number of overtures from potential buyers. Relypsa is working with investment bank Centerview Partners Holdings LLC to review...
-
BDC Investors Take Note: This Midcap's Credit Quality Is Deteriorating
Thursday, March 3, 2016 - 9:55am | 249Cantor Fitzgerald's David J. Chiaverini downgraded the rating on Garrison Capital Inc (NASDAQ: GARS) to Hold, while lowering the price target from $16 to $12. The company reported its 4Q NOI at $0.41 per share, ahead of the estimate and the consensus and driven by lower-than-expected management...
-
'Planet Apple' Makes Apple Worth $195/Share
Monday, June 8, 2015 - 8:54am | 287In a report published Monday, Cantor Fitzgerald analyst Brian J. White maintained a Buy rating on Apple Inc. (NASDAQ: AAPL), with a price target of $195, ahead of the company's annual Worldwide Developers Conference (WWDC). In the rpeort Cantor Fitzgerald noted, "WWDC is primarily focused on...
-
The Latest 'Apple Barometer' Is In
Monday, April 13, 2015 - 9:48am | 295Cantor Fitzgerald issued an industry report on Taiwan barometer sales, specifically highlighting suppliers for Apple Inc. (NASDAQ: AAPL). Analysts Brian White and Isabel Zhu noted that barometer sales declined sharply in February and well below seasonality. Final Apple Barometer sales in...
-
SunTrust's Top 10 Questions For Twitter
Wednesday, November 12, 2014 - 12:45pm | 474SunTrust analyst Robert Peck listed his Top 10 questions to ask management at Twitter Inc (NYSE: TWTR) for its analyst day on Wednesday, noting it could be a "watershed moment." Cantor Fitzgerald also listed its Top Ten recently. Twitter recently traded at $39.74, up 0.38 percent....